Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding or hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

Organon & Co.

In a report released today, Koji Ikeda from Bank of America Securities reiterated a Buy rating on JFrog, with a price target of $110.00. According ...

JFrog (FROG) Gets a Buy from Bank of America Securities

TD Cowen analyst Andrew Sherman reiterated a Buy rating on JFrog yesterday and set a price target of $120.00. Sherman covers the Technology sector,...

JFrog (FROG) Gets a Buy from TD Cowen

Logitech International (($CH:LOGN)) has held its Q1 earnings call. Read on for the main highlights of the call. Logitech’s latest earnings call str...

Logitech Earnings Call Highlights Growth Amid Supply Risks

Barclays analyst Tim Long maintained a Hold rating on Logitech today and set a price target of $101.00. According to TipRanks, Long is a 5-star ana...

Barclays Sticks to Its Hold Rating for Logitech (LOGI)

Origin Enterprises plc ( ($GB:OGN) ) has provided an announcement. Origin Enterprises plc has disclosed a transaction involving a person closely as...

Origin Enterprises Reports Small Share Purchase by Associate of Non-Executive Director

Organon ( ($OGN) ) has shared an update. On July 23, 2026, Organon held a virtual special meeting of stockholders to vote on a proposed merger unde...

Organon Shareholders Approve Merger with Sun Pharma

Organon ( ($OGN) ) has issued an announcement. On April 26, 2026, Organon agreed to be acquired through a merger in which it will become a wholly o...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	OGN	$13.63	+0.18%	781.47K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	OGN	$13.63	+0.2%	781.47K
3
4
5
6

OGN

OGN

Get Organon & Co. Data in Excel

Get Organon & Co. Data in Excel